Friday, February 24, 2017 4:36:08 PM
Similar allegations were made when I identified the error of them using the mean instead of the median.
Several months went by before it was finally accepted that yes, they did use the mean instead of the median.
Similar allegations were made when I said the Info Arm contained many psPD patients. And yes, NWBO characterized these patients as the sickest of the sick.
Several months went by before Dr. Liau confirmed my assertion that there were many psPD patients in the Info Arm. (and yes, psPD patients live far longer than true ePD patients)
I said patients could receive more than 6 months of Temodar in this trial. Many said I was wrong. The protocol says I am right.
I said the partial hold was FDA mandated and many thought I was nuts. Finally NWBO lawyers said it was FDA imposed in a legal filing.
People here seems to think Macdonald requires a confirmatory scan. It does not. That's pretty basic and, frankly, I am amazed people are arguing otherwise. Have patience, I'll be proven correct (actually, it's written in B&W, but apparently people still deny it)
But getting to your point:
I beg to differ. This is an investment forum. Evaluating the strengths and limitations of the supporting scientific research is integral to that.
Unless you chose to just believe everything you read.
Ioannidis wrote a very thought compelling paper you might benefit from reading if you are going to invest in biotech:
Why Most Published Research Findings Are False
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM